BG105616A - Pharmaceutical compositions of analgesic effect - Google Patents
Pharmaceutical compositions of analgesic effectInfo
- Publication number
- BG105616A BG105616A BG105616A BG10561601A BG105616A BG 105616 A BG105616 A BG 105616A BG 105616 A BG105616 A BG 105616A BG 10561601 A BG10561601 A BG 10561601A BG 105616 A BG105616 A BG 105616A
- Authority
- BG
- Bulgaria
- Prior art keywords
- compound
- methyl
- analgesic
- pharmaceutical compositions
- analgesic effect
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 abstract 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 3
- GMSNIKWWOQHZGF-UHFFFAOYSA-N 3-methyl-9H-xanthine Chemical compound O=C1NC(=O)N(C)C2=C1N=CN2 GMSNIKWWOQHZGF-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract 2
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 229960004559 theobromine Drugs 0.000 abstract 2
- RYQVRAILJXPCMZ-UHFFFAOYSA-N 3-methyl-7-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]purine-2,6-dione Chemical compound O1C(C)=NC(CN2C=3C(=O)NC(=O)N(C)C=3N=C2)=N1 RYQVRAILJXPCMZ-UHFFFAOYSA-N 0.000 abstract 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 abstract 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960000212 aminophenazone Drugs 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 229960004126 codeine Drugs 0.000 abstract 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 abstract 1
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 abstract 1
- 229960002065 drotaverine Drugs 0.000 abstract 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 229960000905 indomethacin Drugs 0.000 abstract 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 230000002048 spasmolytic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Abstract
The Subject of the invention is a pharmaceutical composition comprising an active ingredient as analgesic compound and a compound of xanthine structure where the ratio of the analgesic and the xanthine derivatives is (1-20):1, advantageously 10:1. An analgesic compound preferably morphine, aminophenazone, analgin, acetyl-salicylic acid, indomethacin, ibuprofen, diclophenac, codeine, more preferably analgin, S(+)ibuprofen, diclophenac, as a compound of xanthine structure of 3-methylxanthine, theobromine, or CH-13584((1H-purine-2,6-dion-3,7-dihydro-3-methyl-7/5-methyl-1,2,4 -oxadiazole-2-yl/methyl), preferably theobromine is used. The composition of the invention may contain as further active ingredient a smooth muscle spasmolytic, preferably drotaverine. 6 claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9802716A HUP9802716A3 (en) | 1998-11-25 | 1998-11-25 | Pharmaceutical composition of analgesic activity |
| PCT/HU1999/000079 WO2000030715A1 (en) | 1998-11-25 | 1999-11-23 | Composition containing an analgesic and a xanthine or a xanthine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105616A true BG105616A (en) | 2002-01-31 |
Family
ID=89997413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105616A BG105616A (en) | 1998-11-25 | 2001-06-18 | Pharmaceutical compositions of analgesic effect |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1131135A1 (en) |
| AU (1) | AU1510200A (en) |
| BG (1) | BG105616A (en) |
| CZ (1) | CZ20011847A3 (en) |
| EA (1) | EA004375B1 (en) |
| EE (1) | EE200100281A (en) |
| HR (1) | HRP20010403A2 (en) |
| HU (1) | HUP9802716A3 (en) |
| PL (1) | PL348631A1 (en) |
| SK (1) | SK6872001A3 (en) |
| WO (1) | WO2000030715A1 (en) |
| YU (1) | YU37001A (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG65576B1 (en) * | 2002-04-17 | 2009-01-30 | ПИРИМОВА Румяна | Composition of an analgesic, suitable in particular for headache and migraine |
| GB0910375D0 (en) | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| GB0919893D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| AU2015201845B2 (en) * | 2009-11-13 | 2015-11-05 | Infirst Healthcare Limited | Drug combination with theobromine and its use in therapy |
| WO2013005226A1 (en) * | 2011-07-04 | 2013-01-10 | Zota Health Care Ltd | A novel combined pharmaceutical composition containing diclofenac and methods of making and using the same |
| US8853189B2 (en) | 2012-05-31 | 2014-10-07 | Prima Innovations, Llc | Antispasmodic 1,2-Diols and 1,2,3-triols |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU582513B2 (en) * | 1984-12-26 | 1989-03-23 | Eugene M. Laska | Method for using musculoskeletal relaxants |
| EP0719156A1 (en) * | 1993-09-07 | 1996-07-03 | The Procter & Gamble Company | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
| GB9613457D0 (en) * | 1996-06-27 | 1996-08-28 | Procter & Gamble | Pharmaceutical compositions |
-
1998
- 1998-11-25 HU HU9802716A patent/HUP9802716A3/en unknown
-
1999
- 1999-11-23 WO PCT/HU1999/000079 patent/WO2000030715A1/en not_active Application Discontinuation
- 1999-11-23 CZ CZ20011847A patent/CZ20011847A3/en unknown
- 1999-11-23 PL PL99348631A patent/PL348631A1/en unknown
- 1999-11-23 EA EA200100581A patent/EA004375B1/en not_active IP Right Cessation
- 1999-11-23 YU YU37001A patent/YU37001A/en unknown
- 1999-11-23 EE EEP200100281A patent/EE200100281A/en unknown
- 1999-11-23 SK SK687-2001A patent/SK6872001A3/en unknown
- 1999-11-23 AU AU15102/00A patent/AU1510200A/en not_active Abandoned
- 1999-11-23 EP EP99957378A patent/EP1131135A1/en not_active Withdrawn
-
2001
- 2001-05-25 HR HR20010403A patent/HRP20010403A2/en not_active Application Discontinuation
- 2001-06-18 BG BG105616A patent/BG105616A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20010403A2 (en) | 2002-06-30 |
| HUP9802716A2 (en) | 2000-06-28 |
| EP1131135A1 (en) | 2001-09-12 |
| EE200100281A (en) | 2002-08-15 |
| EA004375B1 (en) | 2004-04-29 |
| PL348631A1 (en) | 2002-06-03 |
| HU9802716D0 (en) | 1999-01-28 |
| AU1510200A (en) | 2000-06-13 |
| YU37001A (en) | 2004-05-12 |
| CZ20011847A3 (en) | 2002-07-17 |
| SK6872001A3 (en) | 2002-05-09 |
| EA200100581A1 (en) | 2001-12-24 |
| WO2000030715A1 (en) | 2000-06-02 |
| HUP9802716A3 (en) | 2000-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
| WO2003002136A3 (en) | Stable formulation of modified glp-1 | |
| WO2003013433A3 (en) | Sequestered antagonist formulations | |
| CA2229597A1 (en) | Oral fast-dissolving compositions for dopamine agonists | |
| DE69720988T2 (en) | Non-polar spray or capsule for buccal use | |
| CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
| WO1995031985A3 (en) | Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies | |
| CA2457361A1 (en) | Opioid agonist formulations with releasable and sequestered antagonist | |
| SE8804629A (en) | ||
| EP2281555A3 (en) | Once-a-day oxycodone formulations | |
| MY118371A (en) | Tetrahydrolipstatin containing compositions | |
| WO2003045437A8 (en) | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene | |
| CA2251886A1 (en) | An oral pharmaceutical formulation containing ibandronate | |
| WO2002008217A3 (en) | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | |
| KR910000703A (en) | Antagonists of Tetrazol Stimulating Amino Acid Receptors | |
| CA2325739A1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| DK1383752T3 (en) | Deuterated 3-piperidinopropiophenones as well as drugs containing these compounds | |
| BG105616A (en) | Pharmaceutical compositions of analgesic effect | |
| NZ244320A (en) | Acylals of imidazole-5-carboxylic acid, preparation and pharmaceutical compositions thereof | |
| YU242789A (en) | New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining | |
| MXPA03010672A (en) | Therapeutic compositions for repairing chondropathy. | |
| IT9019793A0 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCEDURE FOR THEIR PREPARATION AND RELATED THERAPEUTIC USE | |
| WO2000064427A3 (en) | Lamivudine containing pharmaceutical formulation | |
| CA2356306A1 (en) | Sulfated phosphatidylinositols, their preparation and use | |
| IL104821A (en) | Octahydro-3-hydroxy-2, 6-methano-2h-quinolizin-8-yl ester of 5-chloro-2, 3-dihydro-2, 2-dimethylbenzofuran-7-carboxylic acid its preparation pharmaceutical compositions and use as 5-ht3-receptor antagonist |